Understanding how a protein called RAD23 affects ALS

RAD23 Control of ALS phenotypes

NIH-funded research Northwestern University · NIH-11088716

This project explores how a protein called RAD23 contributes to the buildup of harmful proteins in ALS, hoping to find new ways to protect nerve cells.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionNorthwestern University NIH-funded
Lab location1 site (Chicago, United States)
Project IDNIH-11088716 on NIH RePORTER

What this research studies

In ALS, nerve cells struggle with a buildup of damaged proteins, a problem linked to how cells manage their protein balance, called proteostasis. This project focuses on a protein named RAD23, which is involved in clearing out these harmful proteins. Researchers believe that RAD23 might actually slow down this cleanup process, making the disease worse. They will use advanced imaging and lab tests to understand how RAD23 works and then test if reducing RAD23 can protect nerve cells in different animal models of ALS, including mice.

Who could benefit from this research

Good fit: This foundational research is for patients living with Amyotrophic Lateral Sclerosis (ALS) who may benefit from future therapies developed from these findings.

Not a fit: Patients seeking immediate treatment or direct participation in a clinical trial will not find direct benefit from this early-stage laboratory research.

Why it matters

Potential benefit: If successful, this work could lead to new treatments that help nerve cells clear out harmful proteins, potentially slowing the progression of ALS.

How similar studies have performed: Previous laboratory studies in various model systems have shown that reducing RAD23 can help clear harmful proteins and improve cell health.

Where this research is happening

Chicago, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Amyotrophic Lateral Sclerosis Motor Neuron Disease
Last reviewed 2026-06-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.